<DOC>
	<DOC>NCT01189695</DOC>
	<brief_summary>The objective of this study is to determine efficacy of ritonavir-boosted lopinavir monotherapy as a maintenance regimen in HIV-1-infected patients who previously failed Non-nucleoside reverse transcriptase inhibitors (NNRTI) based regimens and currently received salvage protease-inhibitor (PI) based regimens.</brief_summary>
	<brief_title>Maintenance Boosted Lopinavir Monotherapy Following Salvage Protease-inhibitor (PI) Based Regimen in HIV With Non-nucleoside Reverse Transcriptase Inhibitors (NNRTI) Based Regimen Failure</brief_title>
	<detailed_description />
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<criteria>age 1860 years documented HIV infection previously failed to NNRTIbased regimens no history of failing PIbased regimens receiving ritonavirboosted PI + OBRs(such as NRITs, etravirine, raltegravir) having HIV1 RNA &lt;50 copies/ml for at least prior 6 months Pregnant or breastfeeding woman HBV coinfection that had to treated with TDF, FTC or 3TC had to received medications known to have potential significant drug interaction with LPV/r life expectancy less than 6 months serious systemic diseases such as liver cirrhosis ChildPugh B/C, ESRD, malignancy hemoglobin &lt;8 g/dl, platelet &lt;50,000/mm3, AST or ALT &gt;3 ULN, estimated creatinine clearance &lt;50 mL/min</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>HIV or AIDS</keyword>
	<keyword>Lopinavir</keyword>
	<keyword>Ritonavir</keyword>
	<keyword>Anti-Retroviral Agents</keyword>
	<keyword>treatment failure</keyword>
	<keyword>treatment experienced</keyword>
	<keyword>NNRTI failure</keyword>
	<keyword>monotherapy</keyword>
</DOC>